147 related articles for article (PubMed ID: 28125433)
21. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
22. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
23. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
[TBL] [Abstract][Full Text] [Related]
24. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
[TBL] [Abstract][Full Text] [Related]
25. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
26. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
[TBL] [Abstract][Full Text] [Related]
27. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.
Safa M; Kazemi A; Zaker F; Razmkhah F
J Recept Signal Transduct Res; 2011 Jun; 31(3):256-63. PubMed ID: 21619452
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
29. Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
Park GB; Hur DY; Kim D
Anticancer Res; 2015 May; 35(5):2699-708. PubMed ID: 25964548
[TBL] [Abstract][Full Text] [Related]
30. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
31. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
33. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
34. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
35. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
36. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
[TBL] [Abstract][Full Text] [Related]
37. Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.
Safa M; Tavasoli B; Manafi R; Kiani F; Kashiri M; Ebrahimi S; Kazemi A
Tumour Biol; 2015 May; 36(5):3919-30. PubMed ID: 25589462
[TBL] [Abstract][Full Text] [Related]
38. Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage.
Mishra D; Singh S; Narayan G
Asian Pac J Cancer Prev; 2016; 17(8):3865-9. PubMed ID: 27644631
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
Yoshida A; Takemura H; Inoue H; Miyashita T; Ueda T
Cancer Res; 2006 Jun; 66(11):5772-80. PubMed ID: 16740716
[TBL] [Abstract][Full Text] [Related]
40. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Wang YA; Johnson SK; Brown BL; Dobson PR
Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]